The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach.
Aysegul ErmanWilliam W L WongJordan J FeldPaul GrootendorstMurray D KrahnPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
We present a clinical decision tool for informing treatment timing for various CHC subpopulations. In general, findings suggest that patients with at least moderate fibrosis should be treated promptly regardless of active drug use.